Literature DB >> 18367444

X-ray structure of 4,4'-dihydroxybenzophenone mimicking sterol substrate in the active site of sterol 14alpha-demethylase (CYP51).

Ali Nasser Eddine1, Jens P von Kries, Mikhail V Podust, Thulasi Warrier, Stefan H E Kaufmann, Larissa M Podust.   

Abstract

A universal step in the biosynthesis of membrane sterols and steroid hormones is the oxidative removal of the 14alpha-methyl group from sterol precursors by sterol 14alpha-demethylase (CYP51). This enzyme is a primary target in treatment of fungal infections in organisms ranging from humans to plants, and development of more potent and selective CYP51 inhibitors is an important biological objective. Our continuing interest in structural aspects of substrate and inhibitor recognition in CYP51 led us to determine (to a resolution of 1.95A) the structure of CYP51 from Mycobacterium tuberculosis (CYP51(Mt)) co-crystallized with 4,4'-dihydroxybenzophenone (DHBP), a small organic molecule previously identified among top type I binding hits in a library screened against CYP51(Mt). The newly determined CYP51(Mt)-DHBP structure is the most complete to date and is an improved template for three-dimensional modeling of CYP51 enzymes from fungal and prokaryotic pathogens. The structure demonstrates the induction of conformational fit of the flexible protein regions and the interactions of conserved Phe-89 essential for both fungal drug resistance and catalytic function, which were obscure in the previously characterized CYP51(Mt)-estriol complex. DHBP represents a benzophenone scaffold binding in the CYP51 active site via a type I mechanism, suggesting (i) a possible new class of CYP51 inhibitors targeting flexible regions, (ii) an alternative catalytic function for bacterial CYP51 enzymes, and (iii) a potential for hydroxybenzophenones, widely distributed in the environment, to interfere with sterol biosynthesis. Finally, we show the inhibition of M. tuberculosis growth by DHBP in a mouse macrophage model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367444      PMCID: PMC2397474          DOI: 10.1074/jbc.M801145200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  Characterization and catalytic properties of the sterol 14alpha-demethylase from Mycobacterium tuberculosis.

Authors:  A Bellamine; A T Mangla; W D Nes; M R Waterman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors.

Authors:  L M Podust; T L Poulos; M R Waterman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  Essential role for cholesterol in entry of mycobacteria into macrophages.

Authors:  J Gatfield; J Pieters
Journal:  Science       Date:  2000-06-02       Impact factor: 47.728

4.  Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450.

Authors:  K Asai; N Tsuchimori; K Okonogi; J R Perfect; O Gotoh; Y Yoshida
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

5.  The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands.

Authors:  R M Blair; H Fang; W S Branham; B S Hass; S L Dial; C L Moland; W Tong; L Shi; R Perkins; D M Sheehan
Journal:  Toxicol Sci       Date:  2000-03       Impact factor: 4.849

6.  Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans.

Authors:  Patrick Marichal; Luc Koymans; Staf Willemsens; Danny Bellens; Peter Verhasselt; Walter Luyten; Marcel Borgers; Frans C S Ramaekers; Frank C Odds; Hugo Vanden Bossche
Journal:  Microbiology       Date:  1999-10       Impact factor: 2.777

7.  Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

Authors:  S Perea; J L López-Ribot; W R Kirkpatrick; R K McAtee; R A Santillán; M Martínez; D Calabrese; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

8.  Absorption of sunscreens across human skin: an evaluation of commercial products for children and adults.

Authors:  R Jiang; M S Roberts; D M Collins; H A Benson
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

9.  Pestalone, a new antibiotic produced by a marine fungus in response to bacterial challenge.

Authors:  M Cueto; P R Jensen; C Kauffman; W Fenical; E Lobkovsky; J Clardy
Journal:  J Nat Prod       Date:  2001-11       Impact factor: 4.050

10.  Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem.

Authors:  S L Kelly; D C Lamb; D E Kelly
Journal:  FEMS Microbiol Lett       Date:  1999-11-15       Impact factor: 2.742

View more
  17 in total

1.  The use of small molecule high-throughput screening to identify inhibitors of the proteinase 3-NB1 interaction.

Authors:  M Choi; C Eulenberg; S Rolle; J P von Kries; F C Luft; R Kettritz
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Conformational plasticity and structure/function relationships in cytochromes P450.

Authors:  Thomas C Pochapsky; Sophia Kazanis; Marina Dang
Journal:  Antioxid Redox Signal       Date:  2010-10       Impact factor: 8.401

3.  Three-dimensional model of lanosterol 14 alpha-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding.

Authors:  Chunquan Sheng; Zhenyuan Miao; Haitao Ji; Jianzhong Yao; Wenya Wang; Xiaoying Che; Guoqiang Dong; Jiaguo Lü; Wei Guo; Wannian Zhang
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

4.  Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.

Authors:  Andrew G S Warrilow; Colin J Jackson; Josie E Parker; Timothy H Marczylo; Diane E Kelly; David C Lamb; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 5.  The Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Hugues Ouellet; Jonathan B Johnston; Paul R Ortiz de Montellano
Journal:  Arch Biochem Biophys       Date:  2009-07-25       Impact factor: 4.013

6.  Two approaches to discovering and developing new drugs for Chagas disease.

Authors:  J H McKerrow; P S Doyle; J C Engel; L M Podust; S A Robertson; R Ferreira; T Saxton; M Arkin; I D Kerr; L S Brinen; C S Craik
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

7.  Evolutionary trace analysis of CYP51 family: implication for site-directed mutagenesis and novel antifungal drug design.

Authors:  Chunquan Sheng; Shuanghong Chen; Haitao Ji; Guoqiang Dong; Xiaoyin Che; Wenya Wang; Zhenyuan Miao; Jianzhong Yao; Jiaguo Lü; Wei Guo; Wannian Zhang
Journal:  J Mol Model       Date:  2009-07-11       Impact factor: 1.810

8.  Spin equilibrium and O₂-binding kinetics of Mycobacterium tuberculosis CYP51 with mutations in the histidine-threonine dyad.

Authors:  Gareth K Jennings; Anuja Modi; Justin E Elenewski; Caroline M Ritchie; Thuy Nguyen; Keith C Ellis; John C Hackett
Journal:  J Inorg Biochem       Date:  2014-04-12       Impact factor: 4.155

9.  Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.

Authors:  Chiung-Kuang Chen; Siegfried S F Leung; Christophe Guilbert; Matthew P Jacobson; James H McKerrow; Larissa M Podust
Journal:  PLoS Negl Trop Dis       Date:  2010-04-06

10.  Expanding the binding envelope of CYP51 inhibitors targeting Trypanosoma cruzi with 4-aminopyridyl-based sulfonamide derivatives.

Authors:  Debora F Vieira; Jun Yong Choi; William R Roush; Larissa M Podust
Journal:  Chembiochem       Date:  2014-04-25       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.